Krsnaa Diagnostics: Q3 FY26 Earnings Call Transcript Released
Krsnaa Diagnostics released its Q3 FY26 earnings call transcript. Revenue was ₹1,812 million (approx. 181.2 crore), up 4% YoY. The company recovered over ₹130 crore in government receivables. Normalized EBITDA was ₹474 million (approx. 47.4 crore) with a 26% margin, and normalized PAT was ₹168 million (approx. 16.8 crore) with a 9% margin. The B2C segment saw 8x YoY revenue growth.
The release of an earnings call transcript provides detailed insights into the company's financial performance, strategic direction, and management commentary. This information is material for investors and analysts, influencing their understanding and potentially their investment decisions.
The announcement is a transcript of an earnings call, which is primarily informational. While the company discussed positive aspects like receivables recovery and B2C growth, the overall financial performance for the quarter was impacted by seasonality and expansion costs, leading to a neutral sentiment.
Krsnaa Diagnostics Limited has released the transcript of its earnings conference call held on February 06, 2026, to discuss the unaudited financial results for the quarter and nine months ended December 31, 2025. The call featured management including Chairman Rajendra Mutha and Managing Director Yash Mutha, along with Group CEO Mitesh Dave.
During the call, the management highlighted Krsnaa's unique, capital-intensive, radiology-led diagnostics platform built on a public-private partnership (PPP) framework. This model, despite requiring higher upfront investments and offering services at significantly lower prices than market rates, has maintained EBITDA and PAT positive status since inception. The company's integrated network spans 18 states and union territories, comprising 190 CT and MRI centers, over 4,000 collection centers, and around 140 pathology laboratories, having served over 81 million patients.
For Q3 FY26, revenue from operations stood at ₹1,812 million (approximately 181.2 crore), a 4% year-on-year growth. The quarter experienced seasonality and temporary operational pauses to accelerate the recovery of government receivables, with over ₹130 crore recovered, strengthening the company's cash position. Collections in Q3 were over ₹100 crore higher than Q3 of the previous year. Margins were influenced by cost absorption related to expansion initiatives, such as the Rajasthan pathology rollout, which is considered a timing issue. Normalized EBITDA was ₹474 million (approximately 47.4 crore) with a 26% margin, and normalized PAT was ₹168 million (approximately 16.8 crore) with a 9% margin.
The company also discussed the growing traction in its B2C segment, with retail revenue increasing 8x year-on-year and contributing approximately 8% to the overall group's revenue in 9MFY26. The launch of the first Apulki Healthcare Hospital in Pune, a PPP-based cancer and cardiac care hospital, was highlighted as a strategic extension into integrated tertiary care.
Leadership updates included the departure of CFO Mr. Pawan Daga, with the company assuring that a strong financial leadership team is in place and a successor search is underway. The management expressed confidence in their strategy, focusing on profitable growth across PPP and retail segments, operational excellence, and capital efficiency to build a trusted healthcare platform.
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.